Can you take Enfamil D-Vi-Sol with Magnesium amino acids chelate?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- Enfamil D-Vi-Sol (cholecalciferol)
- magnesium amino acids chelate
Drug interactions
Moderate drug interactions
Moderate:
cholecalciferol magnesium amino acids chelate
Applies to: Enfamil D-Vi-Sol (cholecalciferol) and magnesium amino acids chelate
Using cholecalciferol together with magnesium amino acids chelate can lead to elevated magnesium blood levels, particularly in individuals with reduced kidney function. Symptoms of high magnesium levels may include nausea, vomiting, flushing, drowsiness, dizziness, confusion, muscle weakness, reduced reflexes, low blood pressure, slow heart rate, and impaired breathing. You should seek medical attention if you experience these symptoms. If you are on dialysis and treated with cholecalciferol or other vitamin D medications, you should generally avoid taking products that contain magnesium without first talking to your doctor, as high levels of magnesium over time can lead to bone problems. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
cholecalciferol Food/Lifestyle
Applies to: Enfamil D-Vi-Sol (cholecalciferol)
Treatment with cholecalciferol may require you to adjust your dietary intake of foods which contain natural or added calcium, phosphate (organic and inorganic), and vitamin D or grapefruit. Ingesting too much vitamin D or having elevated calcium and/or phosphorus levels in the blood and urine can lead to toxic effects, such as having an irregular heart rhythm, seizures, kidney stones, and eventual calcification of your blood vessels, cornea and/or the soft tissues in your body. Consumption of grapefruit and grapefruit juice may also alter the blood levels and effects of cholecalciferol. Your doctor will monitor the levels of calcium and phosphorus in your blood during treatment with cholecalciferol. Please speak with your healthcare team to determine if you require a specialized diet, particularly if you have reduced kidney function, and to discuss any other questions or concerns you have. You may require additional monitoring or a dose adjustment of cholecalciferol if your diet changes. Fortified foods will state on their labeling how much calcium, phosphate, and/or vitamin D has been added. The National Institutes of Health, Office of Dietary Supplements also provides information on which foods contain calcium, phosphorus, and vitamin D. You should avoid abrupt changes in your dietary calcium intake and seek medical attention if you experience early symptoms of vitamin D intoxication such as weakness, fatigue, headache, drowsiness, vertigo, ringing in the ears, loss of appetite, nausea, vomiting, constipation, dry mouth, metallic taste, muscle pain, bone pain, muscle incoordination, and low muscle tone. Late symptoms may include frequent urination, excessive thirst, weight loss, conjunctivitis ("pink eye"), light sensitivity, runny nose, itching, increased body temperature, and irregular heart rhythm. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Arrhythmia, Liver Disease, Hypercalcemia, Malabsorption Syndrome, and Renal Dysfunction.
Arrhythmia
Moderate:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a moderate potential interaction with Arrhythmia.
Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
Biliary Obstruction
Moderate:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a moderate potential interaction with Biliary Obstruction.
Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcitriol (active form) may be considered in patients with compromised hepatic function.
Hypercalcemia
Major:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a major potential interaction with Hypercalcemia.
Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
Liver Disease
Moderate:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a moderate potential interaction with Liver Disease.
Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcitriol (active form) may be considered in patients with compromised hepatic function.
Malabsorption Syndrome
Major:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a major potential interaction with Malabsorption Syndrome.
Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
Phosphate Imbalance
Moderate:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a moderate potential interaction with Phosphate Imbalance.
Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
Renal Dysfunction
Moderate:
Enfamil D-Vi-Sol
The cholecalciferol in Enfamil D-Vi-Sol has a moderate potential interaction with Renal Dysfunction.
Ergocalciferol and cholecalciferol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
Report options
More resources
Enfamil D-Vi-Sol
A total of 116 drugs are known to interact with Enfamil D-Vi-Sol.
- Enfamil d-vi-sol is in the drug class vitamins.
- Enfamil d-vi-sol is used to treat the following conditions:
magnesium amino acids chelate
A total of 67 drugs are known to interact with magnesium amino acids chelate.
- Magnesium amino acids chelate is in the drug class minerals and electrolytes.
- Magnesium amino acids chelate is used to treat Hypomagnesemia.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.